Mini-CHOP and Rituximab in Patients Aged Over 80 Years
This trial is active, not recruiting.
|Condition||diffuse large b-cell lymphoma|
|Sponsor||Lymphoma Study Association|
|Start date||April 2006|
|End date||April 2010|
|Trial size||150 participants|
|Trial identifier||NCT01087424, LNH03-7B|
The purpose of the study is to evaluate efficacy and safety of R-miniCHOP for elderly patients with diffuse large B-Cell lymphoma (DLBC) Lymphoma aged over 80 years by measuring the overall survival.
|Endpoint classification||safety/efficacy study|
|Intervention model||single group assignment|
Induction : 3 cycles every 3 weeks Consolidation :3 cycles every 3 weeks
Evaluating efficacy of R-miniCHOP by overall survival
time frame: 2 years overall survival
Evaluating R-miniCHOP efficacy by Event free survival
time frame: 2 years event free survival
Male or female participants at least 80 years old.
- Patient with histologically proven CD20+ diffuse large B-cell lymphoma (WHO classification). DLBCL with some small cell infiltration in bone marrow or lymph node may be included.
- Aged over 80 years.
- Ann Arbor stage I bulky, II, III or IV
- Age-adjusted International Prognostic Index equal to 0, 1, 2 and 3.
- Patient non previously treated.
- ECOG performance status ≤ 2.
- With a minimum life expectancy of 3 months.
- Negative HIV, HBV and HCV serologies test ≤ 4 weeks (except after vaccination).
- Having previously signed a written informed consent
- Any other histological type of lymphoma.
- Any history of treated or non-treated indolent lymphoma.
- Central nervous system or meningeal involvement by lymphoma.
- Contra-indication to any drug contained in the chemotherapy regimens.
- Any serious active disease (according to the investigator's decision).
- Poor renal function (creatinin level>150µmol/l), poor hepatic function (total bilirubin level>30mmol/l, transaminases>2.5 maximum normal level) unless these abnormalities are related to the lymphoma.
- Poor bone marrow reserve as defined by neutrophils <1.5 G/l or platelets <100 G/l, unless related to bone marrow infiltration.
- Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.
- Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.
- Adult patient under tutelage.
|Official title||Phase II Study of Mini-CHOP Plus Rituximab in Non Previously Treated Patients Aged Over 80 Years With CD 20+ Diffuse Large B-Cell Lymphoma|
Call for more information